Abstract：
BACKGROUND: Currently, bladder cancer detection is based on cytology and cystoscopy. White light cystoscopy (WLC) is an invasive procedure and may under-detect flat lesions. Blue light cystoscopy (BLC) and narrow band imaging (NBI) cystoscopy are new modalities that could improve the detection of non-muscle invasive bladder cancer (NMIBC) and its recurrence or progression to muscle invasive bladder cancer. We present a systematic review on BLC and NBI cystoscopy for bladder cancer diagnosis and NMIBC follow-up.
METHODS: All available systematic reviews and meta-analyses on cystoscopy published in PubMed® between May 2010 and March 2021 were identified and reviewed. The main endpoints were clinical performance for bladder cancer diagnosis and for recurrence or progression detection during NMIBC follow-up, and additional value compared with cytology and/or WLC.
RESULTS: Most of the meta-analyses and systematic reviews published suggest a better sensitivity of BLC and NBI cystoscopy compared to WLC, particularly for the detection of flat lesions (CIS). NBI- and BLC-guided TURBT could decrease the recurrence rates. However, their clinical utility to reduce progression rate and increase survival is still unclear.
CONCLUSIONS: BLC and NBI cystoscopy are efficient techniques for bladder cancer diagnosis and NMIBC follow-up. However, their clinical benefit remains to be confirmed.
METHODS: All available systematic reviews and meta-analyses on cystoscopy published in PubMed® between May 2010 and March 2021 were identified and reviewed. The main endpoints were clinical performance for bladder cancer diagnosis and for recurrence or progression detection during NMIBC follow-up, and additional value compared with cytology and/or WLC.
RESULTS: Most of the meta-analyses and systematic reviews published suggest a better sensitivity of BLC and NBI cystoscopy compared to WLC, particularly for the detection of flat lesions (CIS). NBI- and BLC-guided TURBT could decrease the recurrence rates. However, their clinical utility to reduce progression rate and increase survival is still unclear.
CONCLUSIONS: BLC and NBI cystoscopy are efficient techniques for bladder cancer diagnosis and NMIBC follow-up. However, their clinical benefit remains to be confirmed.
摘要：
背景：目前，膀胱癌的检测是基于细胞学和膀胱镜检查。白光膀胱镜检查（WLC）是一种侵入性手术，可能对扁平病变的检测不足。蓝光膀胱镜检查（BLC）和窄带成像（NBI）膀胱镜检查是可以改善非肌层浸润性膀胱癌（NMIBC）及其复发或进展为肌层浸润性膀胱癌的新方法。我们对BLC和NBI膀胱镜检查在膀胱癌诊断和NMIBC随访中的应用进行了系统评价。
方法：确定并审查了2010年5月至2021年3月在PubMed®上发表的所有关于膀胱镜检查的系统评价和荟萃分析。主要终点是膀胱癌诊断和NMIBC随访期间复发或进展检测的临床表现，以及与细胞学和/或WLC相比的附加价值。
结果：发表的大多数荟萃分析和系统评价表明，与WLC相比，BLC和NBI膀胱镜检查的敏感性更好，特别是对于扁平病变（CIS）的检测。NBI和BLC引导的TURBT可降低复发率。然而,它们在降低进展率和增加生存率方面的临床效用尚不清楚.
结论：BLC和NBI膀胱镜检查是膀胱癌诊断和NMIBC随访的有效技术。然而,其临床获益仍有待证实。
方法：确定并审查了2010年5月至2021年3月在PubMed®上发表的所有关于膀胱镜检查的系统评价和荟萃分析。主要终点是膀胱癌诊断和NMIBC随访期间复发或进展检测的临床表现，以及与细胞学和/或WLC相比的附加价值。
结果：发表的大多数荟萃分析和系统评价表明，与WLC相比，BLC和NBI膀胱镜检查的敏感性更好，特别是对于扁平病变（CIS）的检测。NBI和BLC引导的TURBT可降低复发率。然而,它们在降低进展率和增加生存率方面的临床效用尚不清楚.
结论：BLC和NBI膀胱镜检查是膀胱癌诊断和NMIBC随访的有效技术。然而,其临床获益仍有待证实。
